Frequency of splicing factor mutations in MPNs, AML derived from MPNs, de novo AML, and AML derived from MDSs
| Disease . | Mutational frequency, % . | |||
|---|---|---|---|---|
| SF3B1 . | U2AF1 . | ZRSR2 . | SRSF2 . | |
| Primary myelofibrosis (n = 38) | 5.3 | 2.6 | 5.6 | 2.6 |
| De novo AML (n = 54) | 3.7 | 1.9 | 5.6 | 5.6 |
| Secondary AML from MDS (n = 42) | 4.8 | 9.5 | 2.4 | 4.8 |
| MPNs that later transformed to AML (n = 17) | 0 | 0 | 0 | 11.8 |
| Secondary AML from MPNs (n = 53) | 3.8 | 5.7 | 1.8 | 18.9* |
| Disease . | Mutational frequency, % . | |||
|---|---|---|---|---|
| SF3B1 . | U2AF1 . | ZRSR2 . | SRSF2 . | |
| Primary myelofibrosis (n = 38) | 5.3 | 2.6 | 5.6 | 2.6 |
| De novo AML (n = 54) | 3.7 | 1.9 | 5.6 | 5.6 |
| Secondary AML from MDS (n = 42) | 4.8 | 9.5 | 2.4 | 4.8 |
| MPNs that later transformed to AML (n = 17) | 0 | 0 | 0 | 11.8 |
| Secondary AML from MPNs (n = 53) | 3.8 | 5.7 | 1.8 | 18.9* |
P < .05 compared with frequency in all other disease (2-tailed, Fisher exact test).